Purchase this article with an account.
M. Fossarello, E. Peiretti, M. Vinci, F. Orru`; Effect of Intrastromal Bevacizumab Injection on Corneal Neovascularization: An in vivo Evaluation. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5703.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
to determine the effect of intrastromal bevacizumab injections on corneal neovessels (CNV).
ten eyes were studied in 10 patients with an average age of 64.5 +/- 16.2 years. Patients underwent peripheral corneal intrastromal bevacizumab injections using a 30 G needle at a concentration of 5 mg/0.2 mL. .Intraocular pressure, best-corrected visual acuity, neovascular net extent, anterior segment photography, corneal fluorescein angiography, pachymetry, corneal sensitivity and specular microscopy were recorded preoperatively and postoperatively.
the minimum follow-up period was 6 months. CNVs started to regress within the first 4 days after the injection, and regressed completely by the end of the fourth week in four patients, and regressed partially in six patients. CNV regressed completely after 3 monthly injections in four out of these six patients. . In two patient regression of CNV was not complete. No systemic or local side effects were observed.
1 to 3 corneal intrastromal 5 mg/ 0,2 mL bevacizumab injections may be effective in reducing corneal neovascularization in humans without observed side effects.
This PDF is available to Subscribers Only